TY - JOUR
T1 - In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization
AU - Palaskas, Nicolas L.
AU - Deswal, Anita
N1 - Funding Information:
Boehringer Ingelheim and Eli Lilly.
PY - 2020/11/17
Y1 - 2020/11/17
N2 - SOURCE CITATION: Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. 32865377.
AB - SOURCE CITATION: Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. 32865377.
UR - http://www.scopus.com/inward/record.url?scp=85096253960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096253960&partnerID=8YFLogxK
U2 - 10.7326/ACPJ202011170-051
DO - 10.7326/ACPJ202011170-051
M3 - Comment/debate
C2 - 33197352
AN - SCOPUS:85096253960
SN - 0003-4819
VL - 173
SP - JC51
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 10
ER -